Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
Zug, Switzerland – December 13, 2024 – Galderma today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe...
Zug, Switzerland – December 13, 2024 – Galderma today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe...
